• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    9/28/23 1:35:26 PM ET
    $ALGN
    $BBIO
    $BCLI
    $CVS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALGN alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    BCLI PUT TRADE BULLISH 10/20/23 $1.00 $200.0K 17.5K 11.8K
    CVS CALL TRADE BEARISH 11/17/23 $72.50 $172.0K 7.1K 1.1K
    ICPT CALL TRADE BEARISH 01/19/24 $15.00 $33.1K 738 613
    ZBH CALL SWEEP BEARISH 10/20/23 $115.00 $28.8K 244 532
    JNJ CALL SWEEP BULLISH 12/15/23 $160.00 $44.2K 444 493
    EYPT PUT SWEEP BULLISH 01/19/24 $17.50 $304.6K 61 476
    BBIO PUT SWEEP BEARISH 05/17/24 $20.00 $46.1K 2.1K 371
    REGN PUT SWEEP BEARISH 01/17/25 $770.00 $534.0K 167 74
    ALGN PUT SWEEP BEARISH 04/19/24 $310.00 $29.1K 164 37
    HZNP CALL SWEEP BULLISH 11/17/23 $100.00 $29.5K 571 18

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • Regarding BCLI (NASDAQ:BCLI), we observe a put option trade with bullish sentiment. It expires in 22 day(s) on October 20, 2023. Parties traded 2500 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $200.0K, with a price of $80.0 per contract. There were 17518 open contracts at this strike prior to today, and today 11865 contract(s) were bought and sold.

    • For CVS (NYSE:CVS), we notice a call option trade that happens to be bearish, expiring in 50 day(s) on November 17, 2023. This event was a transfer of 1000 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $172.0K, with a price of $172.0 per contract. There were 7153 open contracts at this strike prior to today, and today 1160 contract(s) were bought and sold.

    • Regarding ICPT (NASDAQ:ICPT), we observe a call option trade with bearish sentiment. It expires in 113 day(s) on January 19, 2024. Parties traded 85 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $33.1K, with a price of $390.0 per contract. There were 738 open contracts at this strike prior to today, and today 613 contract(s) were bought and sold.

    • For ZBH (NYSE:ZBH), we notice a call option sweep that happens to be bearish, expiring in 22 day(s) on October 20, 2023. This event was a transfer of 165 contract(s) at a $115.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $175.0 per contract. There were 244 open contracts at this strike prior to today, and today 532 contract(s) were bought and sold.

    • Regarding JNJ (NYSE:JNJ), we observe a call option sweep with bullish sentiment. It expires in 78 day(s) on December 15, 2023. Parties traded 118 contract(s) at a $160.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $375.0 per contract. There were 444 open contracts at this strike prior to today, and today 493 contract(s) were bought and sold.

    • Regarding EYPT (NASDAQ:EYPT), we observe a put option sweep with bullish sentiment. It expires in 113 day(s) on January 19, 2024. Parties traded 272 contract(s) at a $17.50 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $304.6K, with a price of $1120.0 per contract. There were 61 open contracts at this strike prior to today, and today 476 contract(s) were bought and sold.

    • For BBIO (NASDAQ:BBIO), we notice a put option sweep that happens to be bearish, expiring in 232 day(s) on May 17, 2024. This event was a transfer of 174 contract(s) at a $20.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $46.1K, with a price of $265.0 per contract. There were 2147 open contracts at this strike prior to today, and today 371 contract(s) were bought and sold.

    • For REGN (NASDAQ:REGN), we notice a put option sweep that happens to be bearish, expiring in 477 day(s) on January 17, 2025. This event was a transfer of 86 contract(s) at a $770.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $534.0K, with a price of $6210.0 per contract. There were 167 open contracts at this strike prior to today, and today 74 contract(s) were bought and sold.

    • Regarding ALGN (NASDAQ:ALGN), we observe a put option sweep with bearish sentiment. It expires in 204 day(s) on April 19, 2024. Parties traded 8 contract(s) at a $310.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.1K, with a price of $3640.0 per contract. There were 164 open contracts at this strike prior to today, and today 37 contract(s) were bought and sold.

    • Regarding HZNP (NASDAQ:HZNP), we observe a call option sweep with bullish sentiment. It expires in 50 day(s) on November 17, 2023. Parties traded 18 contract(s) at a $100.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 571 open contracts at this strike prior to today, and today 18 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGN
    $BBIO
    $BCLI
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    Align Technology Inc.
    $ALGN
    3/17/2026$200.00Equal Weight → Overweight
    Barclays
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    BridgeBio Pharma Inc.
    $BBIO
    3/10/2026Outperform
    William Blair
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/6/2026$923.00Overweight
    Barclays
    Zimmer Biomet Holdings Inc.
    $ZBH
    2/20/2026Mkt Perform
    William Blair
    Align Technology Inc.
    $ALGN
    2/9/2026$200.00Hold → Buy
    HSBC Securities
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Align Tech upgraded by Barclays with a new price target

    Barclays upgraded Align Tech from Equal Weight to Overweight and set a new price target of $200.00

    3/17/26 7:53:01 AM ET
    $ALGN
    Industrial Specialties
    Health Care

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    William Blair initiated coverage on BridgeBio Pharma

    William Blair initiated coverage of BridgeBio Pharma with a rating of Outperform

    3/10/26 8:40:05 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $ALGN
    $BBIO
    $BCLI
    $CVS
    SEC Filings

    View All

    Amendment: SEC Form 13F-HR/A filed by Johnson & Johnson

    13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)

    3/18/26 11:57:35 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 13F-HR/A filed by Johnson & Johnson

    13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)

    3/18/26 11:38:20 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    3/13/26 4:22:49 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kumar Neil sold $5,501,068 worth of shares (80,000 units at $68.76) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/16/26 6:05:14 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP and CHRO Winkler Lori sold $250,849 worth of shares (2,650 units at $94.66), decreasing direct ownership by 21% to 10,224 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    3/16/26 4:12:46 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End

    Health Zones effort aims to improve health care access, healthy food and chronic condition support in CharlotteCHARLOTTE, N.C., March 18, 2026 /PRNewswire/ -- The CVS Health Foundation today announced the launch of its Health Zone in Charlotte with a $2.24 million investment in the Westside Wellness Collab, led by Local Initiatives Support Corporation (LISC) Charlotte to expand access to health care, healthy food and chronic condition support in Charlotte's Historic West End. "Families deserve access to quality care, healthy food and the support networks that make long‑term well

    3/18/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

    Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatmentSPRING HOUSE, Pa., March 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40

    3/18/26 7:49:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End

    Health Zones effort aims to improve health care access, healthy food and chronic condition support in CharlotteCHARLOTTE, N.C., March 18, 2026 /PRNewswire/ -- The CVS Health Foundation today announced the launch of its Health Zone in Charlotte with a $2.24 million investment in the Westside Wellness Collab, led by Local Initiatives Support Corporation (LISC) Charlotte to expand access to health care, healthy food and chronic condition support in Charlotte's Historic West End. "Families deserve access to quality care, healthy food and the support networks that make long‑term well

    3/18/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Michael Campbell as Chief Commercial Officer

    – Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of

    2/18/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $ALGN
    $BBIO
    $BCLI
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/14/24 3:24:53 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 3:10:08 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 1:22:34 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials